CD28 expression by peripheral blood lymphocytes as a potential predictor of the development of de novo malignancies in long-term survivors after liver transplantation

Liver Transplantation

Volumn 17, Issue 3, 2011, Pages 299-305

  Boleslawski, Emmanuel ^a,b   Othman, Samia Ben ^a   Aoudjehane, Lynda ^a   Chouzenoux, Sandrine ^c   Scatton, Olivier ^d   Soubrane, Olivier ^d   Calmus, Yvon ^a,c,d   Delhem, Nadira ^e   Conti, Filomena ^a,c,d  

^a INSERM   (France)

^b UNIV LILLE   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CD28 ANTIGEN; CD38 ANTIGEN; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS;

ADULT; AGE; ANTIGEN EXPRESSION; ARTICLE; CANCER RISK; CD8+ T LYMPHOCYTE; CLINICAL PRACTICE; CONTROLLED STUDY; DE NOVO MALIGNANCY; FEMALE; FLOW CYTOMETRY; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEOPLASM; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL LYMPHOCYTE; PREDICTION; PRIORITY JOURNAL;

EID: 79952419928     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.22232     Document Type: Article

References (23)

1. Le Moine A, Goldman M, Abramowicz D,. Multiple pathways to allograft rejection. Transplantation 2002; 73: 1373-1381. (Pubitemid 34547453)
2. Dong VM, Yuan X, Coito AJ, Waaga AM, Sayegh MH, Chandraker A,. Mechanisms of targeting CD28 by signaling monoclonal antibody in acute and chronic allograft rejection. Transplantation 2002; 73: 1310-1317. (Pubitemid 34454281)
3. Larsen CP, Elwood ET, Alexander DZ, Ritchie SC, Hendrix R, Tucker-Burden C, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996; 381: 434-438. (Pubitemid 26162734)
4. Malavasi F, Funaro A, Roggero S, Horenstein A, Calosso L, Mehta K,. Human CD 38: a glycoprotein in search of a function. Immunol Today 1994; 15: 95-97.
5. Belles-Isles M, Houde I, Lachance JG, Noël R, Kingma I, Roy R,. Monitoring of cytomegalovirus infections by the CD8+CD38+ T-cell subset in kidney transplant recipients. Transplantation 1998; 65: 279-282. (Pubitemid 28099227)
6. Boleslawski E, BenOthman S, Grabar S, Correia L, Podevin P, Chouzenoux S, et al. CD25, CD28 and CD38 expression in peripheral blood lymphocytes as a tool to predict acute rejection after liver transplantation. Clin Transplant 2008; 22: 494-501.
7. Haagsma EB, Hagens VE, Schaapveld M, van den Berg AP, de Vries EG, Klompmaker IJ, et al. Increased cancer risk after liver transplantation: a population-based study. J Hepatol 2001; 34: 84-91. (Pubitemid 32102556)
8. Herrero JI, Lorenzo M, Quiroga J, Sangro B, Pardo F, Rotellar F, et al. De novo neoplasia after liver transplantation: an analysis of risk factors and influence on survival. Liver Transpl 2005; 11: 89-97. (Pubitemid 40124447)
9. Herrero JI, Alegre F, Quiroga J, Pardo F, Inarrairaegui M, Sangro B, et al. Usefulness of a program of neoplasia surveillance in liver transplantation. A preliminary report. Clin Transplant 2009; 23: 532-536.
10. Fung JJ, Jain A, Kwak EJ, Kusne S, Dvorchik I, Eghtesad B,. De novo malignancies after liver transplantation: a major cause of late death. Liver Transpl 2001; 7: S109-S118.
11. Oo YH, Gunson BK, Lancashire RJ, Cheng KK, Neuberger JM,. Incidence of cancers following orthotopic liver transplantation in a single center: comparison with national cancer incidence rates for England and Wales. Transplantation 2005; 80: 759-764. (Pubitemid 41443757)
12. Herrero JI,. De novo malignancies following liver transplantation: impact and recommendations. Liver Transpl 2009; 15 (suppl 2): S90-S94.
13. Kowalski R, Post D, Schneider MC, Britz J, Thomas J, Deierhoi M, et al. Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management. Clin Transplant 2003; 17: 77-88. (Pubitemid 36833776)
14. Boleslawski E, Conti F, Sanquer S, Podevin P, Chouzenoux S, Batteux F, et al. Defective inhibition of peripheral CD8+ T cell IL-2 production by anti-calcineurin drugs during acute liver allograft rejection. Transplantation 2004; 77: 1815-1820. (Pubitemid 38822202)
15. Chaux P, Moutet M, Faivre J, Martin F, Martin M,. Inflammatory cells infiltrating human colorectal carcinomas express HLA class II but not B7-1 and B7-2 costimulatory molecules of the T-cell activation. Lab Invest 1996; 74: 975-983. (Pubitemid 26152665)
16. Chen L, Ashe S, Brady WA, Hellstrom I, Hellstrom KE, Ledbetter JA, et al. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992; 71: 1093-1102. (Pubitemid 23016545)
17. Denfeld RW, Dietrich A, Wuttig C, Tanczos E, Weiss JM, Vanscheidt W, et al. In situ expression of B7 and CD28 receptor families in human malignant melanoma: relevance for T-cell-mediated anti-tumor immunity. Int J Cancer 1995; 62: 259-265.
18. Becker JC, Bröcker EB,. Lymphocyte-melanoma interaction: role of surface molecules. Recent Results Cancer Res 1995; 139: 205-214.
19. Chambers CA, Kuhns MS, Egen JG, Allison JP,. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 2001; 19: 565-594. (Pubitemid 32368046)
20. Vivarelli M, Cucchetti A, La Barba G, Ravaioli M, Del Gaudio M, Lauro A, et al. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence. Ann Surg 2008; 248: 857-862.
21. Shubinsky G, Schlesinger M,. The CD38 lymphocyte differentiation marker: new insight into its ectoenzymatic activity and its role as a signal transducer. Immunity 1997; 7: 315-324. (Pubitemid 27446006)
22. Bofill M, Borthwick NJ,. CD38 in health and disease. Chem Immunol 2000; 75: 218-234. (Pubitemid 30088777)
23. van den Berg AP, Twilhaar WN, Mesander G, van Son WJ, van der Bij W, Klompmaker IJ, et al. Quantitation of immunosuppression by flow cytometric measurement of the capacity of T cells for interleukin-2 production. Transplantation 1998; 65: 1066-1071. (Pubitemid 28208425)